Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BLINATUMOMAB Cause Drug ineffective? 345 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 345 reports of Drug ineffective have been filed in association with BLINATUMOMAB (BLINCYTO). This represents 3.8% of all adverse event reports for BLINATUMOMAB.

345
Reports of Drug ineffective with BLINATUMOMAB
3.8%
of all BLINATUMOMAB reports
95
Deaths
100
Hospitalizations

How Dangerous Is Drug ineffective From BLINATUMOMAB?

Of the 345 reports, 95 (27.5%) resulted in death, 100 (29.0%) required hospitalization, and 18 (5.2%) were considered life-threatening.

Is Drug ineffective Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BLINATUMOMAB. However, 345 reports have been filed with the FAERS database.

What Other Side Effects Does BLINATUMOMAB Cause?

Pyrexia (1,064) Acute lymphocytic leukaemia recurrent (977) Cytokine release syndrome (952) Off label use (590) Death (588) Neurotoxicity (530) Headache (335) Neutropenia (265) Febrile neutropenia (262) Therapy non-responder (255)

What Other Drugs Cause Drug ineffective?

ADALIMUMAB (71,926) METHOTREXATE (70,142) ETANERCEPT (60,367) ADAPALENE (52,181) ABATACEPT (35,212) INFLIXIMAB (33,738) TOCILIZUMAB (32,342) RITUXIMAB (32,186) LEFLUNOMIDE (31,396) HYDROXYCHLOROQUINE (31,057)

Which BLINATUMOMAB Alternatives Have Lower Drug ineffective Risk?

BLINATUMOMAB vs BLONANSERIN BLINATUMOMAB vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1 BLINATUMOMAB vs BOCEPREVIR BLINATUMOMAB vs BOCOCIZUMAB BLINATUMOMAB vs BONIVA

Related Pages

BLINATUMOMAB Full Profile All Drug ineffective Reports All Drugs Causing Drug ineffective BLINATUMOMAB Demographics